安替可胶囊联合实时虚拟导航系统引导射频消融治疗不可切除的直肠癌肝转移患者疗效初步研究

doi:10.3969/j.issn.1672-5069.2017.05.017

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (5): 575-579.doi: 10.3969/j.issn.1672-5069.2017.05.017

安替可胶囊联合实时虚拟导航系统引导射频消融治疗不可切除的直肠癌肝转移患者疗效初步研究

曹光材，白江江，齐文海，申连东

716000 陕西省延安市延安大学附属医院肛肠外科

收稿日期:2016-10-13 修回日期:2017-10-17 出版日期:2017-10-10 发布日期:2017-10-17
作者简介:曹光材，男，35岁，硕士研究生，主治医师。主要从事结肠直肠肿瘤的治疗学研究。E-mail:caoguangcai1981@163.com

Efficacy of Antike capsule given after ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system in the treatment of patients with hepatic rectal cancer metastases

Cao Guangcai，Bai Jiangjiang，Qi Wenhai，et al.

Department of Anus & Intestine Surgery，Affiliated Hospital，Yan'an University，Yan’an 716000，Shaanxi Province

Received:2016-10-13 Revised:2017-10-17 Online:2017-10-10 Published:2017-10-17

摘要/Abstract

摘要： 目的探讨安替可胶囊联合实时虚拟导航系统引导下射频消融治疗不可切除的直肠癌肝转移患者的临床疗效。方法 2013年1月～2014年1月我院收治的74例无法手术切除的直肠癌肝转移患者，37例在实时虚拟导航系统引导下行射频消融和FOLFOX6方案化疗，37例观察组在上述治疗的基础上同时给予安替可胶囊口服治疗。采用实体瘤疗效评价标准评价近期疗效，观察两组无疾病进展生存时间（PFS）和生存率。结果观察组近期疗效总有效率为78.4%，明显高于对照组的62.2%（P<0.05）；两组1 a生存率分别为89.2%和83.8%，而观察组2 a生存率则显著高于对照组（67.5%对54.1%，P<0.05）；观察组中位PFS 为12.4个月（95%可信区间为10.0～16.2），明显长于对照组的10.1个月，差异具有统计学意义（P＜0.05）。结论对外科手术不可切除的直肠癌肝转移患者，在实时虚拟导航系统引导下行射频消融治疗，术后给予安替可胶囊口服，疗效确切，安全性较高。

关键词: 肝转移癌, 直肠癌, 射频消融, 实时虚拟导航系统, 安替可

Abstract: Objective To investigate the clinical effects of Antike capsule given after ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system in the treatment of patients with hepatic rectal cancer metastases. Methods 74 patients with hepatic rectal cancer metastases were recruited in our hospital between Jan. 2012 and Jan. 2014，and the participants were randomly divided into two groups. 37 patients in control group were treated with ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system and FOLFOX6 regimen，and another 37 were given Antike orally after radiofrequency ablation and chemotherapy. All patients were followed-up for two years，and the short-term as well as long-term efficacy was evaluated with RECIST and non-progress free survival（PFS）. Results The total effective rate was 78.4% in the observation group， much higher than 62.2% in the control group （P<0.05）；There was no significant difference as respect to 1 a survival rates in the two groups （89.2% vs. 83.8%，P>0.05），while the 2 a survival rate in the observation group was 67.5%，much higher than 54.1% in the control（P<0.05）；the non-PFS in the observation was 12.4 m（95% CI 10.0～16.2），much longer than 10.1 m in the control（P＜0.05）. Conclusion Antike capsule combined with ultrasound-guided radiofrequency ablation in treatment of patients with hepatic rectal cancer metastases has a good efficacy，and worth to study further in clinical practice.

Key words: Hepatic metastases, Rectal cancer, Radiofrequency ablation, Ultrasound-guidance, Antike capsule, Real time virtual sonography navigation system

曹光材，白江江，齐文海，申连东. 安替可胶囊联合实时虚拟导航系统引导射频消融治疗不可切除的直肠癌肝转移患者疗效初步研究[J]. 实用肝脏病杂志, 2017, 20(5): 575-579.

Cao Guangcai，Bai Jiangjiang，Qi Wenhai，et al.. Efficacy of Antike capsule given after ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system in the treatment of patients with hepatic rectal cancer metastases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 575-579.

参考文献

[1] Rossi L，Veltri E，Zullo A，et al． Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice．Future Oncol，2012，8（9）:1193-1197．
[2] Arata R，Itamoto T，Ikeda S，et al． Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases:a report of an unusual case． Surg Case Rep，2016，2（1）:106．
[3] Schmoll HJ，Cunningham D，Sobrero A，et al． Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer:A double blind，randomized phase Ⅲ study （ HORIZON Ⅲ）．J Clin Oncol，2012，30（29）: 3588-3595．
[4] 薛苏阳，李佳睿，张文雷，等. 应用雷替曲塞行介入治疗结直肠癌肝转移的疗效．中国老年学杂志，2014，34：2887-2888．
[5] Tamaoki Y，Beppu T，Sakamoto Y，et al．A 5-year recurrence-
free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy．Surg Case Rep，2015，1（1）:111．
[6] 王文娟，白梅，蔡江涛，等. 肝脏超声造影诊断肝癌术后肝内肿瘤复发的价值探讨. 实用肝脏病杂志，2016，19（2）：214-216．
[7] 中华人民共和国卫生部医政司. 中国常见恶性肿瘤诊治规范. 2版. 北京:北京医科大学中国协和医科大学联合出版社，1996: 16-19．
[8] 洪卫，朱利明，刘碧霞. 安替可胶囊联合化疗治疗晚期胃癌的临床研究. 新中医，2014，46（6）6：171-173．
[9] 卫生部医政司，结直肠癌诊疗规范专家工作组．结直肠诊疗规范（2010年版）. 中华胃肠外科杂志，2010，13（11）:865-875．
[10] 周际昌. 实用肿瘤内科学. 北京:人民卫生出版社，1999：22．
[11] 孙燕. 临床肿瘤内科手册. 4版. 北京:人民卫生出版社，2003：323．
[12] Goos JA，Coupe VM，Diosdado B，et al. Aurora kinase A （AUR-KA） expression in colorectal cancer liver metastasis is associated with poor prognosis． Br J Cancer，2013，109（9）: 2445-2452．
[13] Vog TJ，Dommermuth A，Heinle B，et al． Colorectal cancer liver metastases:long-term survival and progression-free survival after thermal ablation using magnetic sonance-guided laser-induced interstitial thermotherapy in 594 patients:analysis of prognostic factors．Invest Radiol，2014，49（1）:48-56．
[14] Ratti F，Catena M，Di Palo S，et al．Laparoscopic approach for primary colorectal cancer improves outcome of patients undergoing combined open hepatic resection for liver metastases． World J Surg，2015，39（10）:2573-2582．
[15] Sagias G，Yiallouras C，Ioannides K，et al．An MRI-conditional motion phantom for the evaluation of high-intensity focused ultrasound protocols．Int J Med Robot，2016，12（3）:431-441．
[16] Muangkaew P，Cho JY，Han HS，et al．Outcomes of simultaneous major liver resection and colorectal surgery for colorectal liver metastases．J Gastrointest Surg，2016，20（3）:554-563．
[17] Yu J，Liang P．Status and advancement of microwave ablation in China．Int J Hyperthermia，2016，4:1-41．
[18] Fosnight TR，Hooi FM，Keil RD，et al. Echo decorrelation imaging of rabbit liver and VX2 tumor during in vivo ultrasound ablation. Ultrasound Med Biol，2016，pii:S0301-5629（16）30261-30267．
[19] Dong X，Li X，Yu J，et al． Complications of ultrasound-guided percutaneous microwave ablation of renal cell carcinoma. Onco Targets Ther，2016，9:5903-5909．
[20] 娄彦妮，贾立群. 安替可胶囊治疗消化系统肿瘤的文献分析. 中国医院用药评价与分析，2013，13（9）：807-809．

安替可胶囊联合实时虚拟导航系统引导射频消融治疗不可切除的直肠癌肝转移患者疗效初步研究

Efficacy of Antike capsule given after ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system in the treatment of patients with hepatic rectal cancer metastases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马履翔, 张雪松. 超声引导下经皮射频消融治疗小肝癌患者疗效及预后分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 125-128.
[2]	汪华, 赵亚宁. 索拉菲尼治疗进展期原发性肝癌患者有效性及安全性研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 936-939.
[3]	叶璇, 张鹏. 微波消融联合经肝动脉介入栓塞化疗和全身化疗治疗结直肠癌肝转移患者临床疗效比较^*[J]. 实用肝脏病杂志, 2018, 21(6): 955-958.
[4]	胡洪生, 孙少华, 沈丰, 吴红伟, 伍伦, 周文波. 射频消融术联合DC-CIK治疗中晚期肝细胞癌患者疗效及其对生命质量的影响研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 757-760.
[5]	吴泉霖, 何耀鹏. ERCP引导下射频消融联合化疗治疗胆管癌患者疗效及影响预后因素分析[J]. 实用肝脏病杂志, 2018, 21(4): 537-540.
[6]	沈云志, 白彧, 吕承育, 孔德刚. 肝动脉热灌注化疗栓塞联合射频消融治疗原发性肝癌患者近期疗效研究*[J]. 实用肝脏病杂志, 2018, 21(3): 475-476.
[7]	刘大勇, 杨光华, 鲁朝敏. 经肝动脉化疗栓塞联合射频消融术和艾迪治疗原发性肝癌患者疗效及其对外周血T淋巴细胞亚群的影响*[J]. 实用肝脏病杂志, 2018, 21(2): 261-264.
[8]	姜海涛, 张彦梅, 范璐. 结直肠癌肝转移患者动态CT增强扫描影像学表现[J]. 实用肝脏病杂志, 2018, 21(1): 125-126.
[9]	徐言综述, 石翠翠, 范建高审校. 非酒精性脂肪性肝病与结直肠癌[J]. 实用肝脏病杂志, 2018, 21(1): 149-152.
[10]	王保信, 邢宏建. 经肝动脉栓塞化疗治疗结肠癌肝转移患者临床初步研究*[J]. 实用肝脏病杂志, 2017, 20(6): 744-747.
[11]	吴进锋, 白国栋, 程荣. TACE联合射频消融治疗原发性肝癌效果分析[J]. 实用肝脏病杂志, 2017, 20(6): 766-768.
[12]	张伟, 陈刚, 孙密密, 安永, 王永清, 商庆华. 经导管肝动脉化疗栓塞联合射频消融治疗原发性肝癌患者临床疗效评价^*[J]. 实用肝脏病杂志, 2017, 20(4): 472-476.
[13]	王金榜, 庄競, 刘永刚, 李保东, 冯伟宇, 徐冬利, 张辉亮, 程科. 肝肿瘤微创切除术治疗结直肠癌肝转移患者效果研究[J]. 实用肝脏病杂志, 2017, 20(4): 500-501.
[14]	余红星, 陈颖, 刘自鹏, 张丽. 超声引导下经皮射频消融与激光消融治疗微小肝癌患者疗效初步比较研究[J]. 实用肝脏病杂志, 2017, 20(3): 320-323.
[15]	邬振国, 陈永永, 李楠. 射频消融联合TACE治疗原发性肝癌患者疗效及对外周血T细胞亚群的影响[J]. 实用肝脏病杂志, 2017, 20(3): 324-327.